TearScience Inc. has received FDA clearance for a second-generation version of its proprietary device that treats evaporative dry eye by liquefying and evacuating obstructions in the meibomian glands (LipiFlow Thermal Pulsation System).
Morrisville, NC-TearScience has received FDA clearance for a second-generation version of its proprietary device (LipiFlow Thermal Pulsation System) that treats evaporative dry eye by liquefying and evacuating obstructions in the meibomian glands.
The new device includes a more robust graphic user interface than the first-generation device, provides users the ability to treat both eyes simultaneously, and allows for storage of a record of the treatment on the device and on electronic medical record servers, according to the company.
“We are pleased to have received FDA clearance for the second-generation [thermal pulsation device] to offer to our current and future customers,” said Tim Willis, chief executive officer and co-founder of TearScience. “TearScience expects to provide many more enhancements that will assist physicians in treating dry eye sufferers efficiently, effectively, and profitably.”
The second-generation device will be commercially available in March. According to TearScience, physicians currently using the first-generation device will have their systems upgraded to the new system.
For more articles in this issue of Ophthalmology Times eReport, click here.